IN2014DN05972A - - Google Patents

Info

Publication number
IN2014DN05972A
IN2014DN05972A IN5972DEN2014A IN2014DN05972A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A IN 5972DEN2014 A IN5972DEN2014 A IN 5972DEN2014A IN 2014DN05972 A IN2014DN05972 A IN 2014DN05972A
Authority
IN
India
Prior art keywords
diseases associated
present
glucose metabolism
therapeutic agent
abnormal glucose
Prior art date
Application number
Other languages
English (en)
Inventor
Ichiro Hisatome
Shunsuke Tsujimoto
Takashi Shirakura
Shinya Hiramitsu
Original Assignee
Teijin Pharma Ltd
Nat Univ Corp Tottori Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Nat Univ Corp Tottori Univ filed Critical Teijin Pharma Ltd
Publication of IN2014DN05972A publication Critical patent/IN2014DN05972A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN5972DEN2014 2012-01-27 2013-01-25 IN2014DN05972A (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012015351 2012-01-27
PCT/JP2013/051627 WO2013111870A1 (ja) 2012-01-27 2013-01-25 糖尿病の治療薬

Publications (1)

Publication Number Publication Date
IN2014DN05972A true IN2014DN05972A (enrdf_load_html_response) 2015-06-26

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5972DEN2014 IN2014DN05972A (enrdf_load_html_response) 2012-01-27 2013-01-25

Country Status (15)

Country Link
US (1) US20150005506A1 (enrdf_load_html_response)
EP (1) EP2808018B1 (enrdf_load_html_response)
JP (1) JP5924699B2 (enrdf_load_html_response)
KR (1) KR20140134266A (enrdf_load_html_response)
CN (1) CN104066430A (enrdf_load_html_response)
AR (1) AR089812A1 (enrdf_load_html_response)
AU (1) AU2013212865A1 (enrdf_load_html_response)
BR (1) BR112014017902A2 (enrdf_load_html_response)
CA (1) CA2862602A1 (enrdf_load_html_response)
HK (1) HK1201209A1 (enrdf_load_html_response)
IN (1) IN2014DN05972A (enrdf_load_html_response)
MX (1) MX2014008484A (enrdf_load_html_response)
RU (1) RU2014134845A (enrdf_load_html_response)
TW (1) TW201334779A (enrdf_load_html_response)
WO (1) WO2013111870A1 (enrdf_load_html_response)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104610190B (zh) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途
CN104610188B (zh) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 含苯基脒结构的腈基苯噻唑羧酸酰胺类化合物、其制备及用途
CN104628672A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的烷氧苯基噻唑羧酸酰胺类化合物及用途
CN104628673A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途
CN104628671B (zh) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 含苯基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途
KR102473677B1 (ko) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 액정 표시 장치
AR107661A1 (es) 2016-02-19 2018-05-23 Nat Univ Corp Tottori Univ Agente terapéutico o profiláctico para la demencia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69122084T2 (de) * 1990-11-30 1997-04-03 Teijin Ltd., Osaka 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
US8557831B2 (en) * 2004-07-21 2013-10-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
EP1919472B1 (en) * 2005-07-21 2021-09-01 University of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
JP5242393B2 (ja) 2005-08-03 2013-07-24 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド 高血圧症の治療方法
CA2630639A1 (en) * 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
JP2007210978A (ja) * 2006-02-13 2007-08-23 Hiroshima Univ 耐糖能障害、ｉｉ型糖尿病、高脂血症、メタボリックシンドローム、内臓脂肪型肥満、脂肪肝または非アルコール性脂肪性肝炎の予防・治療剤
BRPI0718611A2 (pt) 2006-11-13 2014-02-25 Takeda Pharmaceuticals North America Inc Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase.
EA201270666A1 (ru) * 2007-11-27 2012-12-28 Ардеа Биосайнсиз Инк. Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EA018521B1 (ru) * 2008-03-31 2013-08-30 Си Энд Си Рисерч Лэборетериз Гетероциклические производные
NZ588374A (en) * 2008-04-30 2012-11-30 Wellstat Therapeutics Corp Tetrazole compounds for reducing uric acid
EP2291189B1 (en) * 2008-05-22 2014-10-01 AstraZeneca AB Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
JP2012505925A (ja) * 2008-10-19 2012-03-08 リチャード ジェイ ジョンソン 代謝不均衡に関連付けられる慢性腎疾患を治療するための治療組成物及び方法
US20120219536A1 (en) * 2009-08-24 2012-08-30 Queensland University Of Technology Purine-targeted diagnosis and therapy of wounds
MX336607B (es) * 2010-06-16 2016-01-25 Takeda Pharmaceuticals Usa Inc Formas novedosas de dosificacion de liberacion modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa.
PE20130241A1 (es) * 2010-06-25 2013-03-04 Teijin Pharma Ltd Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal

Also Published As

Publication number Publication date
JPWO2013111870A1 (ja) 2015-05-11
CA2862602A1 (en) 2013-08-01
CN104066430A (zh) 2014-09-24
WO2013111870A1 (ja) 2013-08-01
BR112014017902A2 (pt) 2017-08-22
AR089812A1 (es) 2014-09-17
AU2013212865A1 (en) 2014-08-14
RU2014134845A (ru) 2016-03-20
EP2808018A4 (en) 2015-07-15
EP2808018A1 (en) 2014-12-03
HK1201209A1 (en) 2015-08-28
US20150005506A1 (en) 2015-01-01
KR20140134266A (ko) 2014-11-21
EP2808018B1 (en) 2018-03-14
MX2014008484A (es) 2014-10-14
TW201334779A (zh) 2013-09-01
JP5924699B2 (ja) 2016-05-25

Similar Documents

Publication Publication Date Title
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
IN2015MN00404A (enrdf_load_html_response)
MY183312A (en) Pharmaceutical formulation
AU2012214029A8 (en) Rorgammat inhibitors
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
PH12015502839A1 (en) Antiviral compounds
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX361653B (es) Procedimiento para la preparación de derivados del ácido biliar.
PH12017501426A1 (en) Derivatives of betulin
IN2015DN00185A (enrdf_load_html_response)
JO3530B1 (ar) مركبات بيريدازين 1،4-ثنائية الإرتباط ونظائرها وطرق معالجة نقص smn وحالاته المرضية.
MX2015010971A (es) Derivado novedoso de pirazol.
IN2014MN02106A (enrdf_load_html_response)
AU2012321815A8 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
IN2014DN05972A (enrdf_load_html_response)
MY187718A (en) Pharmaceutical formulations
PH12015501752B1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
MX390763B (es) Compuestos de tetraciclina
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
MX2021010046A (es) Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas.
WO2011123536A8 (en) Polycyclic tetracycline compounds
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
IN2014CN04449A (enrdf_load_html_response)
MY173491A (en) Therapeutic or prophylactic agent for biliary tract diseases
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids